Newsroom

Press Release

NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains

NeoGenomics Schedules its Q4 2015 and Full Year 2015 Earnings Release for March 1, 2016

NeoGenomics Completes Acquisition of Clarient, Inc.

NeoGenomics Launches New Liquid Biopsy Tests for Monitoring Solid Tumors and Predicting Resistance to BTK Inhibitors

NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015

NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services

NeoGenomics Signs Definitive Agreement to Acquire Clarient, Inc.

NeoGenomics Schedules its Q3 2015 Earnings Release for October 29, 2015

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients